Our 2021 IMPACT: thanks to donors like you!

280,000 Social Media followers on five platforms.

500 community members participated in our webinars and podcasts.

500+ caregivers responded to a research survey about the unique challenges of caregiving.

2500 children, teens, parents, siblings, caregivers, and friends attended Family Weekend at 18 Great Wolf Lodge locations in the U.S.

265,000 myDSmoment People engaged in a first-of-its-kind Research Awareness Campaign which invites the community to learn more about Down syndrome research, the steps involved, and how their voices can be amplified.

In 2021, we also...

Continued to offer up-to-date information, communications, and vetted resources regarding COVID-19 and vaccines.

Launched my321, a personal fundraising platform for athletes, families, and advocates to raise funds and advance our mission.

my321
Launched my321, a personal fundraising platform for athletes, families, and advocates to raise funds and advance our mission.
LuMind IDSC officially launched a multi-million-dollar 
LuMind IDSC Research Consortium, with founding 
pharmaceutical collaborators, AbbVie and Merck. 
The Consortium is the first step in bridging academia, 
industry, and experts to build a structured and focused 
translational approach to Down syndrome-related research.

LuMind IDSC led a Critical Path Innovation Meeting (CPIM) with the U.S. Food & Drug Administration (FDA) to help identify and begin to remove some of the barriers to clinical trials in Down syndrome associated Alzheimer’s Disease (DS-AD).

Policymaking at the federal level: CPIM meeting

| FDA employees | 18 |
| life sciences companies | 10 |
| academic and research institutions | 8 |
| community members and caregivers | 5 |
| clinical and medical experts | 5 |

In 2021, we also...

5 peer-reviewed research articles were published in clinical and scientific journals.

LuMind IDSC facilitated the Down syndrome community conversation after the approval of Biogen’s Aduhelm - the first new Alzheimer’s drug approved since 2003, and the first to attack what is believed to be one of the causes of Alzheimer’s disease. LuMind IDSC issued several statements and blogposts, and hosted a webinar related to Aduhelm as a means of sharing accurate information. We do not know at this stage if this drug is safe or effective for people with DS. What remains clear is there is much to learn about the drug and LuMind IDSC is committed to staying actively involved.

Expanded LIFE-DSR, a natural history study in the DS-CTN to include:
- four new biomarkers
- expanded blood collection sub-studies
- two feasibility studies on Alzheimer’s assessment scales designed for people with Down syndrome. Enrollment is ongoing.

170 individuals have enrolled to date

14 sites

10 states

3 sites now enrolling the recently-launched Goal Attainment Scale sub study